According to a new study published this week in the Journal of
Clinical Oncology, men treated for prostate cancer who regularly took
aspirin for other medical conditions were less likely to die of cancer
than patients who were not taking aspirin.
In the study, researchers used the national database from a project
known as CaPSURE (Cancer of the Prostate Strategic Urologic Research
Endeavor) to take a look at almost 6,000 men who had localized prostate
cancer and were treated with either surgery or radiotherapy. Just over
one-third (2,175 of 5,955) were taking anticoagulants, most of which
used aspirin.
The men taking aspirin were less than half as likely as those who
were not taking aspirin to die of prostate cancer over a 10 year period.
Researchers calculated that the prostate cancer death rate for those
taking aspirin was 3 percent, versus 8 percent in those who did not take
aspirin.
In addition to having a low rate of death from prostate cancer, the
aspirin using men were also significantly less likely to experience a
recurrence of prostate cancer or have the disease spread to the bones.
Prostate cancer is the most common cancer among men. It is also the No. 2 cancer killer of men. 
Fitness
